Cangrelor Ticagrelor Transition Study

Completed · Phase 2

Conditions studied: Coronary Artery Disease

In brief

To demonstrate that patients treated with cangrelor can be directly switched to oral ticagrelor and that patients treated with ticagrelor can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.

Key facts

Study ID

NCT01766466

Run by

The Medicines Company

People needed

12

Starts

2013-01-01

Expected to finish

2013-02-01

Last updated by the study team

2014-05-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• greater than / equal to 18 and less than 75 years of age
• Previous myocardial infarction defined by admission to the hospital with elevation of markers of injury or the presence of pathologic q waves on at least 2 contiguous electrocardiogram (ECG) leads.
• OR
• Previous revascularization by percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery.
• AND
• Treatment with aspirin (ASA) 81 mg daily.

Where it is running

• Fletcher Allen Health Care — Burlington, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.